Results of a treat-and-eextend regimen of intravitreal ranibizumab injection for macular edema due to branch retinal vein occlusion

Mika Hosogi, Yuki Morizane, Yusuke Shiode, Shinichiro Doi, Fumiaki Kumase, Shuhei Kimura, Mio Hosokawa, Masayuki Hirano, Shinji Toshima, Kosuke Takahashi, Atsushi Fujiwara, Fumio Shiraga

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To investigate the effectiveness of a treat-and-extend regimen (TAE) of intravitreal ranibizumab injections (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). We retrospectively examined 35 eyes of 35 patients with ME due to BRVO who underwent TAE for 1 year. Patients whose treatment interval extended to 12 weeks were switched to a pro re nata regimen (PRN; TAE to PRN group), while TAE was continued for patients whose treatment interval was less than 12 weeks (continued TAE group). Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and predictive factors for inclusion in the TAE to PRN group were analyzed. BCVA and CRT both improved significantly at 1 year compared with baseline (p<0.001). Sixteen eyes (45.7%) were included in the TAE to PRN group, while 19 eyes (54.3%) were included in the continued TAE group. BCVA in the TAE to PRN group was significantly better than that in the continued TAE group at 1 year (p=0.047). BCVA at baseline and macular BRVO were significant predictive factors for inclusion in the TAE to PRN group. TAE was effective for improving BCVA and CRT. The TAE to PRN group showed significantly better prognosis.

Original languageEnglish
Pages (from-to)39-45
Number of pages7
JournalActa Medica Okayama
Volume72
Issue number1
Publication statusPublished - Jan 1 2018

Keywords

  • Anti-vascular endothelial growth factor
  • Branch retinal vein occlusion
  • Macular edema
  • Ranibizumab
  • Treat-and-extend regimen

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Results of a treat-and-eextend regimen of intravitreal ranibizumab injection for macular edema due to branch retinal vein occlusion'. Together they form a unique fingerprint.

  • Cite this